Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Experimental RNAi02:15

Experimental RNAi

6.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
RNA Interference01:23

RNA Interference

26.1K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.1K
Nuclear Export of mRNA02:31

Nuclear Export of mRNA

7.7K
Before mRNAs are exported to the cytoplasm, it is crucial to check each mRNA for structural and functional integrity. Eukaryotic cells use several different mechanisms, collectively known as mRNA surveillance, to look for irregularities in mRNAs. Irregular or aberrant mRNA are rapidly degraded by various enzymes. If a defective mRNA escapes the surveillance, it would be translated into a protein which would either be non-functional or not function properly. One of the primary irregularities in...
7.7K
mRNA Stability and Gene Expression02:51

mRNA Stability and Gene Expression

5.7K
The structure and stability of mRNA molecules regulates gene expression, as mRNAs are a key step in the pathway from gene to protein. In eukaryotes, the half-life of mRNA varies from a few minutes up to several days. mRNA stability is essential in growth and development. The absence of the proteins regulating its stability, such as tristetraprolin in mice, can cause systemic issues, including bone marrow overgrowth, inflammation, and autoimmunity.
Cis-acting Elements involved in mRNA stability
5.7K
Ribozymes02:47

Ribozymes

12.3K
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can...
12.3K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

[BMIM]OAc promoted one-pot synthesis of pyrazolo[4',3':5,6]pyrido[2,3-<i>d</i>]pyrimidin-5-ones and their antimicrobial activity.

RSC advances·2026
Same author

C-5-Arylidene-Thiazolidine-2,4-Dione Analogs Against Aldose Reductase: Design, Synthesis, Biological Evaluation, and Computational Insights.

Archiv der Pharmazie·2025
Same author

RNA G-Quadruplex RIBOTAC-Mediated Targeted Degradation of lncRNA TERRA.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Development of PROTAC-Based Strategies for Cannabinoid Receptor Type 1 (CB<sub>1</sub>R) Degradation in Cancer.

ACS pharmacology & translational science·2025
Same author

Druglike Molecular Degraders of the Oncogenic RNA-Binding Protein HuR.

JACS Au·2025
Same author

Advancing target validation with PROTAC technology.

Expert opinion on drug discovery·2025
Same journal

Why Next-generation mechanistic models Will transform drug discovery: integrating efficacy and safety.

Expert opinion on drug discovery·2026
Same journal

Toward a nuanced framework for the medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology.

Expert opinion on drug discovery·2026
Same journal

From mitochondrial signal to discovery decision: a reserve-demand framework for translational risk assessment.

Expert opinion on drug discovery·2026
Same journal

Advances in 3D cell culture models for alzheimer's disease drug discovery.

Expert opinion on drug discovery·2026
Same journal

Are patient-derived models of amyotrophic lateral sclerosis a game changer for novel drug discovery?

Expert opinion on drug discovery·2026
Same journal

Unfolding prion misfolding and the challenge of identifying effective therapeutics: is there hope on the horizon?

Expert opinion on drug discovery·2026
查看所有相关文章

相关实验视频

Updated: Jul 26, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.6K

通过向核糖酶的奇默体 (RiboTacs) 进行结构RNA的有针对性的降解.

Salma Haj-Yahia1, Arijit Nandi1, Raphael I Benhamou1

  • 1The Institute for Drug Research of the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Expert opinion on drug discovery
|June 12, 2023
PubMed
概括
此摘要是机器生成的。

子核酶向化马体 (RiboTaCs) 是一种新的药物发现方法,它使用小分子来降解与疾病相关的RNA结构. 这种有针对性的RNA降解策略显示出治疗各种疾病的前景.

关键词:
这是一个RNARNARNARNARNA.在 RNase L 中,里博塔克 (RiboTaC) 是一种有针对性的降解降解.治疗方法 治疗方法

更多相关视频

An Oligonucleotide-based Tandem RNA Isolation Procedure to Recover Eukaryotic mRNA-Protein Complexes
09:45

An Oligonucleotide-based Tandem RNA Isolation Procedure to Recover Eukaryotic mRNA-Protein Complexes

Published on: August 18, 2018

11.1K
Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip
13:34

Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip

Published on: September 29, 2012

27.6K

相关实验视频

Last Updated: Jul 26, 2025

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

9.6K
An Oligonucleotide-based Tandem RNA Isolation Procedure to Recover Eukaryotic mRNA-Protein Complexes
09:45

An Oligonucleotide-based Tandem RNA Isolation Procedure to Recover Eukaryotic mRNA-Protein Complexes

Published on: August 18, 2018

11.1K
Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip
13:34

Method for the Isolation and Identification of mRNAs, microRNAs and Protein Components of Ribonucleoprotein Complexes from Cell Extracts using RIP-Chip

Published on: September 29, 2012

27.6K

科学领域:

  • 生物化学 生物化学
  • 分子生物学分子生物学
  • 药物发现 药物发现 药物发现

背景情况:

  • RNA结构动机对于生物识别和调节至关重要.
  • 功能障碍的RNA结构与许多疾病有关.
  • 用小分子向RNA是一种新兴的治疗策略.

研究的目的:

  • 审查核糖核酶向嵌合体 (RiboTaCs) 的演化和机制.
  • 总结RiboTaCs向的与疾病相关的RNA及其治疗结果.
  • 讨论RiboTaC技术在药物发现中的潜力和挑战.

主要方法:

  • 审查关于RiboTaC战略的现有文献.
  • 在体外和体外验证研究的分析.
  • 与疾病相关的RNA标及其降解效应的总结.

主要成果:

  • RiboTaCs可以选择性地降低结构化RNA目标.
  • 由RiboTaCs降解与疾病相关的RNA减轻了体外和体内疾病的表型.
  • 在临床前模型中,RiboTaC策略已经证明了它的有效性.

结论:

  • RiboTaCs代表了基于RNA的治疗方法的一个有希望的有针对性的降解策略.
  • 需要进一步发展,以应对临床翻译的挑战.
  • RiboTaC技术有可能彻底改变各种疾病的治疗方法.